Trials / Completed
CompletedNCT01830140
A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 466 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or ocular hypertension (OHT).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimatoprost 0.01% | Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks. |
| DRUG | Bimatoprost 0.03% | Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks. |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2014-05-01
- Completion
- 2014-05-01
- First posted
- 2013-04-12
- Last updated
- 2015-05-06
- Results posted
- 2015-05-06
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01830140. Inclusion in this directory is not an endorsement.